Lung cancer screening feasibility study funded

A study to assess the feasibility of undertaking a UK-based screening trial for lung cancer has been commissioned by the National institute for Health Research Health Technology Assessment (NIHR HTA) programme. Lung cancer kills more people worldwide than any other malignancy accounting for around 1.4 million deaths each year, and around 38,000 individuals are diagnosed with the disease in the UK each year.

"The number of deaths from lung cancer has fallen in past years in the UK and this is likely to be due to a decline in tobacco smoking, and possibly greater public awareness. However, there is a large ex-smoking population, who remain at high risk of developing lung cancer," says lead researcher Professor John Field, director of the Roy Castle Lung Cancer Research Programme, at the University of Liverpool. "Screening to detect the disease before patients develop any symptoms is a method that urgently requires evaluation as surgical resection at an early stage of the disease remains the only realistic option for a cure."

The results of the feasibility study will be used to decide whether a pilot study and subsequently a full clinical trial should be commissioned. This would use computerised tomography (CT) to scan people at high-risk of developing lung cancer, and would look at both the benefits and the harms that could result from such a screening programme.

"If the results of the feasibility study are promising it will be important to undertake a randomised control trial to assess if CT scanning is the best way forward. Only then would evidence be available to show whether a National Lung cancer Screening Programme should be considered," says Professor Field. "We are delighted that the HTA has decided to invest in this first stage, which will help inform whether it is feasible to conduct a full trial."

To view the full project details visit www.hta.ac.uk/1752

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients